Abstract
Automatic analysis of increasingly growing literature repositories including data integration to other databases is a powerful tool to propose hypothesis that can be used to plan experiments to validate or disprove the hypothesis. Furthermore, it provides means to evaluate the redundancy of research line in comparison to the published literature. This is potentially beneficial for those developing research in a specific disease which are interested in exploring a particular pathway or set of genes/proteins. In the scope of the integrating book a case will be made addressing proteostasis factors in cancer. The maintenance of proteome homeostasis, known as proteostasis, is a process by which cells regulate protein translation, degradation, subcellular localization, and protein folding and consists of an integrated network of proteins. The ubiquitin-proteasome system plays a key role in essential biological processes such as cell cycle, DNA damage repair, membrane trafficking, and maintaining protein homeostasis. Cells maintain proteostasis by regulating protein translation, degradation, subcellular localization, and protein folding. Aberrant proteostasis leads to loss-of-function diseases (cystic fibrosis) and gain-of-toxic-function diseases (Alzheimer’s, Parkinson’s, and Huntington’s disease). Cancer therapy on the other hand explores inhibition of proteostasis factors to trigger endoplasmic reticulum stress with subsequent apoptosis. Alternatively therapies target deubiquitinases and thereby regulate tumor promoters or suppressors. Furthermore, mutations in specific proteostasis factors are associated with higher risk for specific cancers, e.g., BRCA mutations in breast cancer. This chapter discusses proteostasis protein factors’ association with cancer from a literature mining perspective.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rebholz-Schuhmann D, Oellrich A, Hoehndorf R (2012) Text-mining solutions for biomedical research: enabling integrative biology. Nat Rev Genet 13(12):829–839. doi:10.1038/nrg3337
Deshaies RJ, Joazeiro CA (2009) RING domain E3 ubiquitin ligases. Annu Rev Biochem 78:399–434. doi:10.1146/annurev.biochem.78.101807.093809
Reyes-Turcu FE, Ventii KH, Wilkinson KD (2009) Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 78:363–397. doi:10.1146/annurev.biochem.78.082307.091526
van Wijk SJ, Timmers HT (2010) The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins. FASEB J 24(4):981–993. doi:10.1096/fj.09-136259
Sun Y (2006) E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 8(8):645–654. doi:10.1593/neo.06376
Liu Y, Ye Y (2011) Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy. Cell Res 21(6):867–883. doi:10.1038/cr.2011.75
Perez-Galan P, Mora-Jensen H, Weniger MA, Shaffer AL 3rd, Rizzatti EG, Chapman CM, Mo CC, Stennett LS, Rader C, Liu P, Raghavachari N, Stetler-Stevenson M, Yuan C, Pittaluga S, Maric I, Dunleavy KM, Wilson WH, Staudt LM, Wiestner A (2011) Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 117(2):542–552. doi:10.1182/blood-2010-02-269514
Kane RC, Farrell AT, Sridhara R, Pazdur R (2006) United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 12(10):2955–2960. doi:10.1158/1078-0432.CCR-06-0170
Field-Smith A, Morgan GJ, Davies FE (2006) Bortezomib (Velcadetrade mark) in the treatment of multiple myeloma. Ther Clin Risk Manag 2(3):271–279
Fribley AM, Evenchik B, Zeng Q, Park BK, Guan JY, Zhang H, Hale TJ, Soengas MS, Kaufman RJ, Wang CY (2006) Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem 281(42):31440–31447. doi:10.1074/jbc.M604356200
Carvalho AS, Ribeiro H, Voabil P, Penque D, Jensen ON, Molina H, Matthiesen R (2014) Global mass spectrometry and transcriptomics array based drug profiling provides novel insight into glucosamine induced endoplasmic reticulum stress. Mol Cell Proteomics 13(12):3294–3307. doi:10.1074/mcp.M113.034363
Fribley A, Wang CY (2006) Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol Ther 5(7):745–748
Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107(12):4907–4916. doi:10.1182/blood-2005-08-3531
MacLaren AP, Chapman RS, Wyllie AH, Watson CJ (2001) p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ 8(3):210–218. doi:10.1038/sj.cdd.4400801
Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59(11):2615–2622
Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277(19):16639–16647. doi:10.1074/jbc.M200360200
Wang Q, Li L, Ye Y (2008) Inhibition of p97-dependent protein degradation by Eeyarestatin I. J Biol Chem 283(12):7445–7454. doi:10.1074/jbc.M708347200
Sacco JJ, Coulson JM, Clague MJ, Urbe S (2010) Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB Life 62(2):140–157. doi:10.1002/iub.300
Petrucelli N, Daly MB, Feldman GL (2010) Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med 12(5):245–259. doi:10.1097/GIM.0b013e3181d38f2f
Montes de Oca Luna R, Wagner DS, Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378(6553):203–206. doi:10.1038/378203a0
de Rozieres S, Maya R, Oren M, Lozano G (2000) The loss of mdm2 induces p53-mediated apoptosis. Oncogene 19(13):1691–1697. doi:10.1038/sj.onc.1203468
Pletscher-Frankild S, Palleja A, Tsafou K, Binder JX, Jensen LJ (2015) DISEASES: text mining and data integration of disease-gene associations. Methods 74:83–89. doi:10.1016/j.ymeth.2014.11.020
Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108(2):171–182
Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, Ogata H, Ohta T (2001) The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 276(18):14537–14540. doi:10.1074/jbc.C000881200
Sato K, Sundaramoorthy E, Rajendra E, Hattori H, Jeyasekharan AD, Ayoub N, Schiess R, Aebersold R, Nishikawa H, Sedukhina AS, Wada H, Ohta T, Venkitaraman AR (2012) A DNA-damage selective role for BRCA1 E3 ligase in claspin ubiquitylation, CHK1 activation, and DNA repair. Curr Biol 22(18):1659–1666. doi:10.1016/j.cub.2012.07.034
Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387(6630):296–299. doi:10.1038/387296a0
Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420(1):25–27
Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387(6630):299–303. doi:10.1038/387299a0
Pant V, Lozano G (2014) Dissecting the p53-Mdm2 feedback loop in vivo: uncoupling the role in p53 stability and activity. OncoTarget 5(5):1149–1156
Louria-Hayon I, Grossman T, Sionov RV, Alsheich O, Pandolfi PP, Haupt Y (2003) The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem 278(35):33134–33141. doi:10.1074/jbc.M301264200
Suzuki Y, Nakabayashi Y, Takahashi R (2001) Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci U S A 98(15):8662–8667. doi:10.1073/pnas.161506698
Neil JR, Tian M, Schiemann WP (2009) X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression. J Biol Chem 284(32):21209–21217. doi:10.1074/jbc.M109.018374
Schmidt MH, Dikic I (2005) The Cbl interactome and its functions. Nat Rev Mol Cell Biol 6(12):907–918. doi:10.1038/nrm1762
Kim M, Tezuka T, Tanaka K, Yamamoto T (2004) Cbl-c suppresses v-Src-induced transformation through ubiquitin-dependent protein degradation. Oncogene 23(9):1645–1655. doi:10.1038/sj.onc.1207298
Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC (1999) The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286(5438):309–312
Tanimoto K, Makino Y, Pereira T, Poellinger L (2000) Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 19(16):4298–4309. doi:10.1093/emboj/19.16.4298
Cheng J, Kang X, Zhang S, Yeh ET (2007) SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 131(3):584–595. doi:10.1016/j.cell.2007.08.045
Veena MS, Wilken R, Zheng JY, Gholkar A, Venkatesan N, Vira D, Ahmed S, Basak SK, Dalgard CL, Ravichandran S, Batra RK, Kasahara N, Elashoff D, Fishbein MC, Whitelegge JP, Torres JZ, Wang MB, Srivatsan ES (2014) p16 Protein and gigaxonin are associated with the ubiquitination of NFkappaB in cisplatin-induced senescence of cancer cells. J Biol Chem 289(50):34921–34937. doi:10.1074/jbc.M114.568543
Acknowledgements
The authors would like to acknowledge networking support by the Proteostasis COST Action (BM1307). This work is supported by Fundação para a Ciência e Tecnologia project EXPL/DTP-PIC/0616/2013. R.M. is supported by FCT investigator program 2012. A.S.C. is supported by grant SFRH/BPD/85569/2012 funded by Fundação para a Ciência e Tecnologia.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Carvalho, A.S., Rodríguez, M.S., Matthiesen, R. (2016). Review and Literature Mining on Proteostasis Factors and Cancer. In: Matthiesen, R. (eds) Proteostasis. Methods in Molecular Biology, vol 1449. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3756-1_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3756-1_2
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3754-7
Online ISBN: 978-1-4939-3756-1
eBook Packages: Springer Protocols